CXCR4-targeted PET/CT Imaging in Hematological Malignancies

• Status: Not yet recruiting
• Trial end date: 2024-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The incidence and mortality of hematological malignancies remain high. Although 18F-FDG PET/CT imaging is the most common molecular imaging technique used in clinic, the non-specific uptake of 18F-FDG leads to the problems of false negative or positive in hematological malignancies, which makes it difficult to diagnose and evaluate the efficacy. CXCR4 (C-X-C Chemokine Receptor Type 4) is overexpressed in various hematological malignancies, and is associated with poor prognosis. CXCR4-targeted molecular imaging, such as 68Ga-pentixafor PET/CT imaging, has an important potential in hematological malignancies. Therefore, this study will evaluate the efficacy of CXCR4-targeted PET/CT imaging for diagnosis and staging of hematological malignancies, compared with 18F-FDG PET/CT imaging.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongnan Hospital

Criteria

Inclusion Criteria:

1. Volunteer to participate and sign an informed consent form;

2. 18 ≤ Age ≤ 90 years;

3. Patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies;

4. Willing and able to follow schedule visits, treatment plans and laboratory tests.

Exclusion Criteria:

1. pregnancy or breastfeeding;

2. Allergic to CXCR4-targeted tracers or excipients;

3. Fasting blood glucose level exceeded 11.0 mmol/L prior to injection of 18F-FDG;

4. Those who cannot complete PET/CT scan, including inability to keep supine, claustrophobia, radiation phobia, etc.;

5. Researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.